查看文章

We here report the case of a 59-year-old male patient who developed a stiff-person syndrome (SPS) as a possibly immune-related adverse event after receiving Pembrolizumab as first-line therapy of adenocarcinoma of the lung. In September 2019, a 59-year-old male patient presented to our emergency department with reoccurring painful, immobilizing muscle spasms, stiffness, and falls which had lasted for approximately 10 days. Spasms were triggered by any voluntary movement, sensory, emotional or acoustic stimuli and were located mainly in the legs and the lower back, leading to a lumbar hyperlordosis. The patient reported an improvement of spasm severity and frequency under selfmedication with cannabidiol and baclofen. He suffered from stage IV adenocarcinoma of the lung, treated with the anti-PD-1 antibody pembrolizumab. The patient had suffered from pembrolizumab associated increase in …